Clenoliximab is a monoclonal antibody that primarily targets the CD4 receptor on T cells, which plays a crucial role in the immune response. It is classified as an immunomodulatory agent and has been investigated for its potential therapeutic applications in autoimmune diseases and conditions involving T cell activation. The structure of Clenoliximab consists of a variable region that binds specifically to the CD4 molecule, thereby modulating T cell activity. Its mechanism of action involves inhibiting T cell activation and proliferation, which can be beneficial in managing diseases characterized by excessive immune responses. Clenoliximab has undergone various stages of clinical trials to assess its efficacy and safety profile. As with many monoclonal antibodies, its administration is typically via injection, and it may be associated with side effects related to immune modulation. Overall, Clenoliximab represents a targeted approach in the field of immunotherapy, reflecting the growing trend of utilizing biologics to treat complex immune-related disorders.

Clenoliximab

182912-58-9: Clenoliximab is a monoclonal antibody that primarily targets the CD4 receptor on T cells, which plays a crucial role in the immune response. It is classified as an immunomodulatory agent and has been investigated for its potential therapeutic applications in autoimmune diseases and conditions involving T cell activation. The structure of Clenoliximab consists of a variable region that binds specifically to the CD4 molecule, thereby modulating T cell activity. Its mechanism of action involves inhibiting T cell activation and proliferation, which can be beneficial in managing diseases characterized by excessive immune responses. Clenoliximab has undergone various stages of clinical trials to assess its efficacy and safety profile. As with many monoclonal antibodies, its administration is typically via injection, and it may be associated with side effects related to immune modulation. Overall, Clenoliximab represents a targeted approach in the field of immunotherapy, reflecting the growing trend of utilizing biologics to treat complex immune-related disorders.

<p>Clenoliximab (IDEC-151), a macaque-human chimeric monoclonal antibody (immunoglobulin G4), targets the CD4 molecule on T lymphocytes' surface and is utilized in</p>

<p>A recombinant chimeric antibody targeting human CD4.</p>

CAS 182912-58-9

Clenoliximab

Clenoliximab

Ref: TM-T82708

Clenoliximab

Ref: 3D-CLA1123